SPARC: Prostatectomy +/- Cabozantinib in High-Risk Prostate Cancer Patients - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how effective cabozantinib is at killing prostate cancer cells.

Another purpose of the study is to learn if there is a difference in how often cancer comes back in people who take cabozantinib before having surgery to remove their prostate compared to people who have surgery right away.

What is the Condition Being Studied?

Untreated, High-Risk Prostate Cancer

Who Can Participate in the Study?

Adults with prostate cancer who:
- Plan to have a surgery called a “radical prostatectomy”
- Have not had any previous treatments for their cancer

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Have blood and urine tests
- Be randomly assigned to one of two groups:
- Group A will take cabozantinib (a pill that you take by mouth) every day for 4 weeks before having surgery to remove their prostate
- Group B will have a surgery to remove their prostate immediately

Study Details

Full Title
A Phase II, Open-Label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men with High-Risk Prostate Cancer (SPARC)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00101042
NCT: NCT03964337
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698